Disappointment as Roche's new Alzheimer's drug fails to slow cognitive decline

The Alzheimer’s Society called it ‘disappointing’ after Roche revealed its drug gantenerumab failed to meet its primary target to slow down cognitive decline in people with Alzheimer’s.
Source: Care Feeds